GRASSILLI, EMANUELA
GRASSILLI, EMANUELA
DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE
Editorial: Targeting Bruton Tyrosine Kinase
2022 Brunner, C; Betzler, A; Brown, J; Andreotti, A; Grassilli, E
Emerging actionable targets to treat therapy-resistant colorectal cancers
2022 Grassilli, E; Cerrito, M
p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors
2021 Grassilli, E; Cerrito, M; Bonomo, S; Giovannoni, R; Conconi, D; Lavitrano, M
Identifying novel actionable targets in colon cancer
2021 Cerrito, M; Grassilli, E
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers
2020 Lavitrano, M; Ianzano, L; Bonomo, S; Cialdella, A; Cerrito, M; Pisano, F; Missaglia, C; Giovannoni, R; Romano, G; Mclean, C; Voest, E; D'Amato, F; Noli, B; Ferri, G; Agostini, M; Pucciarelli, S; Helin, K; Leone, B; Canzonieri, V; Grassilli, E
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation
2020 Scagliotti, A; Grassilli, E; Cazzaniga, M; Capizzi, L; Lavitrano, M; Cerrito, M
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
2019 Giordano, F; Vaira, V; Cortinovis, D; Bonomo, S; Goedmakers, J; Brena, F; Cialdella, A; Ianzano, L; Forno, I; Cerrito, M; Giovannoni, R; Ferri, G; Tasciotti, E; Vicent, S; Damarco, F; Bosari, S; Lavitrano, M; Grassilli, E
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer
2019 Basile, D; Gerratana, L; Buonadonna, A; Garattini, S; Perin, T; Grassilli, E; Miolo, G; Cerrito, M; Belluco, C; Bertola, G; De Paoli, A; Cannizzaro, R; Lavitrano, M; Puglisi, F; Canzonieri, V
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
2019 Sala, L; Cirillo, G; Riva, G; Romano, G; Giussani, C; Cialdella, A; Todisco, A; Virtuoso, A; Cerrito, M; Bentivegna, A; Grassilli, E; Ardizzoia, A; Bonoldi, E; Giovannoni, R; Papa, M; Lavitrano, M
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.
2018 Cerrito, M; De Giorgi, M; Pelizzoni, D; Bonomo, S; Digiacomo, N; Scagliotti, A; Bugarin, C; Gaipa, G; Grassilli, E; Lavitrano, M; Giovannoni, R; Bidoli, P; Cazzaniga, M
Simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro
2017 Chisci, E; De Giorgi, M; Zanfrini, E; Testasecca, A; Brambilla, E; Cinti, A; Farina, L; Kutryb Zając, B; Bugarin, C; Villa, C; Grassilli, E; Combi, R; Gaipa, G; Cerrito, M; Rivolta, I; Smolenski, R; Lavitrano, M; Giovannoni, R
A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation
2016 Grassilli, E; Pisano, F; Cialdella, A; Bonomo, S; Missaglia, C; Cerrito, M; Masiero, L; Ianzano, L; Giordano, F; Cicirelli, V; Narloch, R; D’Amato, F; Noli, B; Ferri, G; Leone, B; Stanta, G; Bonin, S; Helin, K; Giovannoni, R; Lavitrano, M
The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells
2016 Romano, G; Santi, L; Bianco, M; Giuffrè, M; Pettinato, M; Bugarin, C; Garanzini, C; Savarese, L; Leoni, S; Cerrito, M; Leone, B; Gaipa, G; Grassilli, E; Papa, M; Lavitrano, M; Giovannoni, R
Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients
2016 Conconi, D; Redaelli, S; Bovo, G; Leone, B; Filippi, E; Ambrosiani, L; Cerrito, M; Grassilli, E; Giovannoni, R; Dalpra', L; Lavitrano, M
GSK3A Is Redundant with GSK3B in Modulating Drug Resistance and Chemotherapy-Induced Necroptosis
2014 Grassilli, E; Ianzano, L; Bonomo, S; Missaglia, C; Cerrito, M; Giovannoni, R; Masiero, L; Lavitrano, M
Inhibition of GSK3B Bypass Drug Resistance of p53-null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2013 Grassilli, E; Narloch, R; Federzoni, E; Ianzano, L; Pisano, F; Giovannoni, R; Romano, G; Masiero, L; Leone, B; Bonin, S; Donada, M; Stanta, G; Helin, K; Lavitrano, M
Combinations of a btk inhibitor and fluorouracil for treating cancers
2014 Cerrito, M; Giovannoni, R; Grassilli, E; Lavitrano, M; Masiero, L; Pisano, F; Romano, G
Methods for determining the sensitivity or resistance of cancer cells to at least one anticancer drug and/or therapeutically active molecule
2014 Conconi, D; Dalpra', L; Grassilli, E; Lavitrano, M
Pharmaceutical kit for use in the treatment of colon and colorectal cancer
2013 Cerrito, M; Giovannoni, R; Grassilli, E; Lavitrano, M; Masiero, L; Pisano, F; Romano, G
NEW ISOFORM OF BRUTON’S TYROSINE KINASE (BTK) PROTEIN
2012 Lavitrano, M; Grassilli, E; Helin, K